News | May 05, 2022
JBCPL emerges as the fastest growing pharma company: Report
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
Center of Excellence for Molecular Diagnostics and Proteomics will enable affordable diagnostics for infectious diseases in India
The management believes that its strong product pipeline, diversified innovative product portfolio, continued expansion into new geographies and FGMP accreditations will help sustain the growth momentum in the coming few years
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Revolution Aspire CT System is manufactured at the company’s new plant launched under the government’s Production Linked Incentives (PLI) Scheme
Subscribe To Our Newsletter & Stay Updated
